Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun:107:107050.
doi: 10.1016/j.yebeh.2020.107050. Epub 2020 Apr 12.

Poverty, insurance, and region as predictors of epilepsy treatment among US adults

Affiliations

Poverty, insurance, and region as predictors of epilepsy treatment among US adults

Magdalena Szaflarski et al. Epilepsy Behav. 2020 Jun.

Abstract

Disparities in epilepsy treatment have previously been reported. In the current study, we examine the role of socioeconomic status, health insurance, place of residence, and sociodemographic characteristics in past-year visit to a neurology or epilepsy provider and current use of antiseizure medications. Multiple years of data were compiled from the National Health Interview Surveys, Sample Adult Epilepsy Modules. The sample (n = 1655) included individuals 18 years and older who have been told by a doctor to have epilepsy or seizures. Independent variables included number of seizures in the past year, health insurance, poverty status, education, region, race/ethnicity, foreign-born status, age, and sex/gender. Two sets of weighted hierarchical logistic regression models were estimated predicting past-year epilepsy visit and current medication use. Accounting for recent seizure activity and other factors, uninsured and people residing outside of the Northeast were less likely to see an epilepsy provider, and people living in poverty were less likely to use medications, relative to their comparison groups. However, no racial/ethnic and nativity-based differences in specialty service or medication use were observed. Further research, including longitudinal studies of care trajectories and outcomes, are warranted to better understand healthcare needs of people with epilepsy, in particular treatment-resistant seizures, and to develop appropriate interventions at the policy, public health, and health system levels.

Keywords: Epilepsy treatment; Health insurance; Healthcare services; National Health Interview Survey; Region; Specialist care.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest MS has received research support and speaking/consulting fees from Greenwich Biosciences, Inc. JGST was a research assistant on a study funded by Greenwich Biosciences, Inc. IM has received support from Kaul Pediatric Research Institute. JPS declares the following: Funding from National Institutes of Health (NIH), National Science Foundation (NSF), Shor Foundation for Epilepsy Research, Department of Defense United States, UCB Pharma, Inc., NeuroPace, Inc., Greenwich Biosciences, Inc., Biogen, Inc., Xenon Pharmaceuticals, Serina Therapeutics, Inc., and Eisai, Inc.; Consulting/advisory boards for SAGE Therapeutics, Inc., Greenwich Biosciences, Inc., NeuroPace, Inc., Upsher-Smith Laboratories, Inc., Medical Association of the State of AL, Serina Therapeutics, Inc., LivaNova, Inc., UCB Pharma, Inc., Lundbeck, SK LifeSciences, and Elite Medical Experts LLC.; and Editorial board member for Epilepsy & Behavior, Journal of Epileptology (associate editor), Epilepsy & Behavior Reports (associate editor), Journal of Medical Science, Epilepsy Currents (contributing editor), and Folia Medica Copernicana. JDW declares no conflicts of interest.

Figures

Figure 1.
Figure 1.
Differences in the predicted probabilities of epilepsy care between selected values of model covariates Notes: Predicted probabilities were calculated in postestimation following the logistic regression models for taking medicine or seeing a specialist (see Model 5 in Tables 1 and 2 for model coefficients). If the difference in probability is negative, then the reference group has a larger probability of the outcome. A difference in probabilities is not significant at .05 if its confidence interval is overlapping 0.

References

    1. Institute of Medicine, Epilepsy across the spectrum: promoting health and understanding. National Academies Press: Washington, DC; 2012. https://www.nap.edu/download/13379. - PubMed
    1. Wiebe S, Camfield P, Jette N, Burneo JG. Epidemiology of epilepsy: prevalence, impact, comorbidity and disparities. Can J Neurol Sci 2009; 36(Suppl 2):S7–16. https://www.ncbi.nlm.nih.gov/pubmed/19760894. - PubMed
    1. Burneo JG, Jette N, Theodore W, Begley C, Parko K, Thurman DJ, et al. Disparities in epilepsy: report of a systematic review by the North American Commission of the International League Against Epilepsy. Epilepsia 2009; 50(10):2285–95. https://www.ncbi.nlm.nih.gov/pubmed/19732134. - PMC - PubMed
    1. Szaflarski M Social determinants of health in epilepsy. Epilepsy Behav 2014;41:283–9. http://www.ncbi.nlm.nih.gov/pubmed/24998313. - PubMed
    1. Szaflarski M, Szaflarski JP, Privitera MD, Ficker DM, Horner RD. Racial/ethnic disparities in the treatment of epilepsy: what do we know? what do we need to know? Epilepsy Behav 2006; 9(2):243–64. http://www.ncbi.nlm.nih.gov/pubmed/16839821. - PubMed

Publication types

MeSH terms